In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States. Metastatic prostate cancer refers … Continue reading "Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer"
The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently published as rapid communication in the Journal of Clinical Oncology. Prostate cancer is the most frequently diagnosed cancer in men … Continue reading "Xtandi® Improves Survival in Advanced Prostate Cancer"